Axon Enterprise Inc. Reduces Stock Holdings in Cellebrite DI Ltd. $CLBT

Axon Enterprise Inc. lessened its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 13.2% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,310,013 shares of the company’s stock after selling 199,328 shares during the period. Cellebrite DI makes up approximately 100.0% of Axon Enterprise Inc.’s portfolio, making the stock its biggest holding. Axon Enterprise Inc.’s holdings in Cellebrite DI were worth $18,052,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Roubaix Capital LLC lifted its stake in Cellebrite DI by 108.1% in the first quarter. Roubaix Capital LLC now owns 303,215 shares of the company’s stock valued at $4,178,000 after purchasing an additional 157,536 shares during the last quarter. Principal Financial Group Inc. grew its holdings in Cellebrite DI by 33.9% during the first quarter. Principal Financial Group Inc. now owns 2,156,166 shares of the company’s stock valued at $29,712,000 after purchasing an additional 545,334 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its position in Cellebrite DI by 28.6% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,350,000 shares of the company’s stock worth $24,341,000 after buying an additional 300,000 shares during the last quarter. UBS Group AG increased its position in Cellebrite DI by 99.0% in the fourth quarter. UBS Group AG now owns 376,376 shares of the company’s stock worth $6,786,000 after buying an additional 187,220 shares during the last quarter. Finally, Walter Public Investments Inc. bought a new stake in shares of Cellebrite DI in the fourth quarter valued at $9,242,000. 45.88% of the stock is owned by institutional investors.

Insider Transactions at Cellebrite DI

In other news, CEO Thomas E. Hogan sold 103,188 shares of Cellebrite DI stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $15.76, for a total value of $1,626,242.88. Following the completion of the transaction, the chief executive officer directly owned 590,777 shares in the company, valued at approximately $9,310,645.52. The trade was a 14.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CRO Marcus Jewell sold 12,658 shares of Cellebrite DI stock in a transaction on Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the transaction, the executive owned 440,101 shares of the company’s stock, valued at approximately $5,620,089.77. This trade represents a 2.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 158,191 shares of company stock valued at $2,479,438 over the last three months. Company insiders own 5.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on CLBT shares. DA Davidson began coverage on Cellebrite DI in a research report on Wednesday, May 27th. They set a “buy” rating and a $20.00 price target on the stock. Needham & Company LLC decreased their price objective on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, May 15th. Finally, Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Cellebrite DI presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.40.

Cellebrite DI Price Performance

Shares of CLBT stock opened at $14.22 on Friday. The company’s fifty day simple moving average is $14.19 and its two-hundred day simple moving average is $14.31. Cellebrite DI Ltd. has a 1 year low of $11.02 and a 1 year high of $19.98. The stock has a market capitalization of $3.55 billion, a price-to-earnings ratio of 50.79, a PEG ratio of 1.76 and a beta of 1.17.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.